Long-term benefits of omalizumab in a patient with severe non-allergic asthma

Francesco Menzella, Roberto Piro, Nicola Facciolongo, Claudia Castagnetti, Anna Simonazzi, Luigi Zucchi

Research output: Contribution to journalArticle

Abstract

Introduction: Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy.Case presentation: We studied a 52-year-old man who has been suffering from severe non allergic steroid-resistant asthma with increased levels of total IgE and a lot of comorbidity. After a 3 years long treatment with omalizumab, he presented a significant improvement in disease control in terms of hospitalizations, exacerbation, quality of life and lung function with good safety profile.Conclusion: Our case shows, after a long follow-up, how omalizumab can be effective in a severe form of non-atopic asthma. It is therefore hoped that further studies can identify indicators that are able to give to clinicians information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic.

Original languageEnglish
Article number9
JournalAllergy, Asthma and Clinical Immunology
Volume7
Issue number1
DOIs
Publication statusPublished - May 24 2011

Fingerprint

Asthma
Immunoglobulin E
Comorbidity
Hospitalization
Therapeutics
Steroids
Monoclonal Antibodies
Quality of Life
Safety
Lung
Omalizumab
anti-IgE antibodies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Immunology

Cite this

Long-term benefits of omalizumab in a patient with severe non-allergic asthma. / Menzella, Francesco; Piro, Roberto; Facciolongo, Nicola; Castagnetti, Claudia; Simonazzi, Anna; Zucchi, Luigi.

In: Allergy, Asthma and Clinical Immunology, Vol. 7, No. 1, 9, 24.05.2011.

Research output: Contribution to journalArticle

Menzella, Francesco ; Piro, Roberto ; Facciolongo, Nicola ; Castagnetti, Claudia ; Simonazzi, Anna ; Zucchi, Luigi. / Long-term benefits of omalizumab in a patient with severe non-allergic asthma. In: Allergy, Asthma and Clinical Immunology. 2011 ; Vol. 7, No. 1.
@article{22b23bfc8da64343ad1da4bf03ee4cce,
title = "Long-term benefits of omalizumab in a patient with severe non-allergic asthma",
abstract = "Introduction: Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy.Case presentation: We studied a 52-year-old man who has been suffering from severe non allergic steroid-resistant asthma with increased levels of total IgE and a lot of comorbidity. After a 3 years long treatment with omalizumab, he presented a significant improvement in disease control in terms of hospitalizations, exacerbation, quality of life and lung function with good safety profile.Conclusion: Our case shows, after a long follow-up, how omalizumab can be effective in a severe form of non-atopic asthma. It is therefore hoped that further studies can identify indicators that are able to give to clinicians information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic.",
author = "Francesco Menzella and Roberto Piro and Nicola Facciolongo and Claudia Castagnetti and Anna Simonazzi and Luigi Zucchi",
year = "2011",
month = "5",
day = "24",
doi = "10.1186/1710-1492-7-9",
language = "English",
volume = "7",
journal = "Allergy, Asthma and Clinical Immunology",
issn = "1710-1484",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Long-term benefits of omalizumab in a patient with severe non-allergic asthma

AU - Menzella, Francesco

AU - Piro, Roberto

AU - Facciolongo, Nicola

AU - Castagnetti, Claudia

AU - Simonazzi, Anna

AU - Zucchi, Luigi

PY - 2011/5/24

Y1 - 2011/5/24

N2 - Introduction: Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy.Case presentation: We studied a 52-year-old man who has been suffering from severe non allergic steroid-resistant asthma with increased levels of total IgE and a lot of comorbidity. After a 3 years long treatment with omalizumab, he presented a significant improvement in disease control in terms of hospitalizations, exacerbation, quality of life and lung function with good safety profile.Conclusion: Our case shows, after a long follow-up, how omalizumab can be effective in a severe form of non-atopic asthma. It is therefore hoped that further studies can identify indicators that are able to give to clinicians information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic.

AB - Introduction: Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy.Case presentation: We studied a 52-year-old man who has been suffering from severe non allergic steroid-resistant asthma with increased levels of total IgE and a lot of comorbidity. After a 3 years long treatment with omalizumab, he presented a significant improvement in disease control in terms of hospitalizations, exacerbation, quality of life and lung function with good safety profile.Conclusion: Our case shows, after a long follow-up, how omalizumab can be effective in a severe form of non-atopic asthma. It is therefore hoped that further studies can identify indicators that are able to give to clinicians information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic.

UR - http://www.scopus.com/inward/record.url?scp=80052268492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052268492&partnerID=8YFLogxK

U2 - 10.1186/1710-1492-7-9

DO - 10.1186/1710-1492-7-9

M3 - Article

C2 - 21609447

AN - SCOPUS:80052268492

VL - 7

JO - Allergy, Asthma and Clinical Immunology

JF - Allergy, Asthma and Clinical Immunology

SN - 1710-1484

IS - 1

M1 - 9

ER -